Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Grand View Research | PRODUCT CODE: 1772200

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1772200

U.S. Lateral Flow Assay Market Size, Share & Trends Analysis Report By Product, By Application, By Technique, By End use, And Segment Forecasts, 2025 - 2033

PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 5950
Printable PDF & Excel (5-User License)
USD 6950
Printable PDF & Excel (Enterprise License)
USD 8950

Add to Cart

U.S. Lateral Flow Assay Market Trends:

The U.S. lateral flow assay market size was valued at USD 2.82 billion in 2024 and is projected to reach USD 4.63 billion by 2033, growing at a CAGR of 6.08% from 2025 to 2033. The rising prevalence of infectious diseases places immense pressure on public health systems worldwide. With increasing urbanization, interconnectivity, antimicrobial resistance, and the rising impact of climate change, experts stress the urgent need for enhanced infectious disease surveillance, prevention, and diagnostic capabilities. The global rise in infectious diseases significantly drives the lateral flow assays (LFA) market by necessitating rapid diagnostic solutions. According to the Centers for Disease Control and Prevention (CDC), tuberculosis (TB) cases in the U.S. increased from 7,874 in 2022 to 10,347 in 2024, reflecting a notable public health challenge.

The mosquito-borne disease testing segment is projected to experience significant growth due to the rising prevalence of mosquito-borne infections, including West Nile virus (WNV), dengue, chikungunya, Zika virus, malaria, and yellow fever. The increasing incidence of these diseases has heightened the demand for rapid and efficient diagnostic solutions, particularly in regions prone to outbreaks. According to the Centers for Disease Control and Prevention (CDC), West Nile virus (WNV) has become endemic in the U.S., with cases reported in all 48 contiguous states and the District of Columbia, predominantly during the summer and fall months. As of November 2024, the CDC recorded 1,466 cases of WNV, while in 2022, 913 human cases were reported, with 70% classified as neuroinvasive and 30% as non-neuroinvasive. The increasing burden of mosquito-borne diseases, alongside ongoing health crises such as COVID-19 and monkeypox, underscores the urgent need for effective diagnostic and surveillance measures.

Public health initiatives also play a crucial role in market expansion. The CDC's Influenza Division International Program focuses on surveillance, pandemic preparedness, research, and vaccination programs to combat influenza. Additionally, the National Association of County and City Health Officials supports local health departments in influenza prevention and control.

U.S. Lateral Flow Assay Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. lateral flow assay market report based on product, application, technique, and end use:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Kits & Reagents
  • Lateral Flow Readers
  • Benchtop Readers
  • Digital Readers
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Clinical Testing
    • Infectious Disease Testing
    • COVID-19
    • Mosquito Borne Disease Testing
    • Malaria Testing
    • Dengue Testing
    • Zika Testing
    • Chikungunya Testing
    • Others
    • Influenza Testing
    • Sexually Transmitted Infection Testing
    • HIV Testing
    • HPV Testing
    • Chlamydia Testing
    • Gonorrhea Testing
    • Syphilis Testing
    • Other STI Testing
    • Hepatitis
    • Tuberculosis
    • Other Infectious Diseases
    • Cardiac Marker Testing
    • Troponin I and T Testing
    • CK-MB Testing
    • BNP and NT-Probnp Testing
    • Myoglobin Testing
    • D-Dimer Testing
    • Other Cardiac Marker Tests
    • Pregnancy & Fertility Testing
    • Pregnancy Testing
    • Fertility Testing
    • Cholesterol Testing/Lipid Profile
    • Drugs of Abuse Testing
    • Other Clinical Tests
  • Veterinary Diagnostics
  • Food Safety & Environment Testing
  • Drug Development & Quality Testing
  • Technique Outlook (Revenue, USD Million, 2021 - 2033)
  • Sandwich Assays
  • Competitive Assays
  • Multiplex Detection Assays
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Home Care
  • Pharmaceutical & Biotechnology Companies
  • Others
Product Code: GVR-4-68040-646-5

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Lateral Flow Assay Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
      • 3.3.1.1. Increasing prevalence of infectious diseases
      • 3.3.1.2. Technological advancements in lateral flow
      • 3.3.1.3. Growing adoption in homecare settings
    • 3.3.2. Market Restraints Analysis
      • 3.3.2.1. Stringent Regulations
    • 3.3.3. Market Opportunities Analysis
      • 3.3.3.1. Growing demand for Point-of-Care (POC) Testing
      • 3.3.3.2. Expanding applications beyond healthcare
    • 3.3.4. Market Challenges Analysis
      • 3.3.4.1. Product Recalls
  • 3.4. U.S. Lateral Flow Assay Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. U.S. Lateral Flow Assay Market: Product Estimates & Trend Analysis

  • 4.1. U.S. Lateral Flow Assay Market: Product Movement Analysis
  • 4.2. U.S. Lateral Flow Assay Market Estimates and Forecasts, by Product 2024 & 2033 (USD Million)
  • 4.3. Kits & Reagents
    • 4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Lateral Flow Readers
    • 4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Benchtop Readers
      • 4.4.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Digital Readers
      • 4.4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Lateral Flow Assay Market: Application Estimates & Trend Analysis

  • 5.1. U.S. Lateral Flow Assay Market: Application Movement Analysis
  • 5.2. U.S. Lateral Flow Assay Market Estimates and Forecasts, by Application 2024 & 2033 (USD Million)
  • 5.3. Clinical Testing
    • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.3.2. Infectious Disease Testing
      • 5.3.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.2.2. COVID-19
        • 5.3.2.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.2.3. Mosquito Borne Disease Testing
        • 5.3.2.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 5.3.2.3.2. Malaria Testing
          • 5.3.2.3.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 5.3.2.3.3. Dengue Testing
          • 5.3.2.3.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 5.3.2.3.4. Zika Testing
          • 5.3.2.3.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 5.3.2.3.5. Chikungunya Testing
          • 5.3.2.3.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 5.3.2.3.6. Others
          • 5.3.2.3.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.2.4. Influenza Testing
        • 5.3.2.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.2.5. Sexually Transmitted Infection Testing
        • 5.3.2.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 5.3.2.5.2. HIV Testing
          • 5.3.2.5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 5.3.2.5.3. HPV Testing
          • 5.3.2.5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 5.3.2.5.4. Chlamydia Testing
          • 5.3.2.5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 5.3.2.5.5. Gonorrhea Testing
          • 5.3.2.5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 5.3.2.5.6. Syphilis Testing
          • 5.3.2.5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 5.3.2.5.7. Other STI Testing
          • 5.3.2.5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.2.6. Hepatitis
        • 5.3.2.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.2.7. Tuberculosis
        • 5.3.2.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.2.8. Other Infectious Diseases
        • 5.3.2.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.3.3. Cardiac Marker Testing
      • 5.3.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.3.2. Troponin I and T Testing
        • 5.3.3.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.3.3. CK-MB Testing
        • 5.3.3.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.3.4. BNP and NT-Probnp Testing
        • 5.3.3.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.3.5. Myoglobin Testing
        • 5.3.3.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.3.6. D-Dimer Testing
        • 5.3.3.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.3.7. Other Cardiac Marker Tests
        • 5.3.3.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.3.4. Pregnancy & Fertility Testing
      • 5.3.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.4.2. Pregnancy Testing
        • 5.3.4.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.4.3. Fertility Testing
        • 5.3.4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.3.5. Cholesterol Testing/Lipid Profile
      • 5.3.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.3.6. Drugs of Abuse Testing
      • 5.3.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.3.7. Other Clinical Tests
      • 5.3.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Veterinary Diagnostics
    • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Food Safety & Environment Testing
    • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Drug Development & Quality Testing
    • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Lateral Flow Assay Market: Technique Estimates & Trend Analysis

  • 6.1. U.S. Lateral Flow Assay Market: Technique Movement Analysis
  • 6.2. U.S. Lateral Flow Assay Market Estimates and Forecasts, by Technique 2024 & 2033 (USD Million)
  • 6.3. Sandwich Assays
    • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Competitive Assays
    • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Multiplex Detection Assays
    • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Lateral Flow Assay Market: End Use Estimates & Trend Analysis

  • 7.1. U.S. Lateral Flow Assay Market: End-use Movement Analysis
  • 7.2. U.S. Lateral Flow Assay Market Estimates and Forecasts, by End-use 2024 & 2033 (USD Million)
  • 7.3. Hospitals & Clinics
    • 7.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4. Diagnostic Laboratories
    • 7.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Home Care
    • 7.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Pharmaceutical & Biotechnology Companies
    • 7.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Other End-use
    • 7.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Abbott
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Bio-Rad Laboratories, Inc
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Siemens Healthineers AG
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. BIOMERIEUX
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. BD
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. QIAGEN
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. QuidelOrtho Corporation
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. F. Hoffmann-La Roche
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. DH Life Sciences, LLC.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Quest Diagnostics
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives
Product Code: GVR-4-68040-646-5

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. lateral flow assay market, by region, 2018 - 2033 (USD Million)
  • Table 3 U.S. lateral flow assay market, by product, 2018 - 2033 (USD Million)
  • Table 4 U.S. lateral flow assay market, by technique, 2018 - 2033 (USD Million)
  • Table 5 U.S. lateral flow assay market, by application, 2018 - 2033 (USD Million)
  • Table 6 U.S. lateral flow assay market, by end-use, 2018 - 2033 (USD Million)

List of Figures

  • Fig. 1 U.S. lateral flow assay market segmentation
  • Fig. 2 Data analysis models
  • Fig. 3 Market formulation and validation
  • Fig. 4 Data validating & publishing
  • Fig. 5 Market research process
  • Fig. 6 Information procurement
  • Fig. 7 Primary research
  • Fig. 8 Value-chain-based sizing & forecasting
  • Fig. 9 QFD modelling for market share assessment
  • Fig. 10 Market formulation & validation
  • Fig. 11 Commodity flow analysis
  • Fig. 12 Market outlook
  • Fig. 13 Segment snapshot-1
  • Fig. 14 Segment snapshot-2
  • Fig. 15 Competitive landscape snapshot
  • Fig. 16 Market trends & outlook
  • Fig. 17 Porter's five force analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 U.S. lateral flow assay market: Product outlook key takeaways
  • Fig. 20 U.S. lateral flow assay market: Product movement analysis
  • Fig. 21 Kits & reagents market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Lateral flow readers market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Benchtop readers market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Digital readers market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 U.S. lateral flow assay market: Application outlook key takeaways
  • Fig. 26 U.S. lateral flow assay market: Application movement analysis
  • Fig. 27 Clinical testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Infectious disease testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Covid-19 market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 Mosquito borne disease testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 Malaria Testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Dengue Testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Zika Testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Chikungunya Testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Influenza testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Sexually transmitted infection testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 HIV testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 HPV testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Chlamydia testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 Gonorrhea testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Syphilis testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Other STI testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Hepatitis market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Tuberculosis market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Other infectious diseases market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Cardiac marker testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Troponin I and t testing
  • Fig. 49 CK-MB testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 BNP and NT-PROBNP testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Myoglobin testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 D-dimer testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Other cardiac marker tests market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 Pregnancy & fertility testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Pregnancy testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 Fertility testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Cholesterol testing/lipid profile market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 58 Drugs of abuse testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Other clinical tests market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 Veterinary diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Food safety & environment testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 Drug development & quality testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 U.S. lateral flow assay market: Technique outlook key takeaways
  • Fig. 64 U.S. lateral flow assay market: Technique movement analysis
  • Fig. 65 Sandwich assays market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 Competitive assays market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 Multiplex detection assays market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 U.S. Lateral Flow Assay market: Test Type outlook key takeaways
  • Fig. 69 U.S. Lateral Flow Assay market: Test Type movement analysis
  • Fig. 70 Lateral flow immunoassay market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 71 Nucleic acid lateral flow assay market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 U.S. Lateral Flow Assay market: End-use outlook key takeaways
  • Fig. 73 U.S. Lateral Flow Assay market: End-use movement analysis
  • Fig. 74 Hospitals & clinics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 75 Diagnostic laboratories market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 Home care market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 77 Pharmaceutical & biotechnology companies market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 78 Other End-use market estimates and forecasts, 2021 - 2033 (USD Million)
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!